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Abstract 
 
Objective: The objective of this selective EBM review is to determine whether or not minoxidil 
is efficacious and safe for the treatment of androgenetic alopecia (AGA) in men, and if so, what 
is the optimal strength and means of delivery.   
 
Study Design:  Review of three double-blind randomized controlled trials studying men (18-49 
y/o) with androgenetic alopecia published in English from 2007-2009. 
 
Data Source: Three articles of double-blind randomized controlled trials found via PubMed.   
 
Outcomes Measured:  Outcomes measured included the efficacy and safety of minoxidil as well 
as the optimal strength and means of delivery of the drug.  For efficacy, parameters used 
included target area hair count (TAHC), subject assessment using rating scale, expert panel or 
investigator assessment via photographic review and then rated on the same scale used by 
subjects.  To assess safety, the studies used subject report of symptoms of scalp irritation, 
investigator examination of signs of scalp irritation, and change in vital signs and/or abnormal 
lab values for systemic effects.  As for the optimal strength and means of delivery, this was 
evaluated based on the way each study was designed.  In the Olsen study, 5% minoxidil foam 
applied twice daily was compared to a placebo, while the Tsuboi study compared application of 
5% minoxidil lotion to 1% minoxidil lotion with both also applied twice daily, and the Shin 
study compared the use of a placebo in the morning and 5% minoxidil/0.01% tretinoin in the 
evening against twice daily application of 5% minoxidil alone.  
 
Results:  The Olsen and Tsuboi studies demonstrated that 5% minoxidil applied twice daily was 
efficacious without significant adverse effects when compared to placebo or 1% minoxidil 
respectively, and the Shin study raised the possibility of combined 5% minoxidil/0.01% tretinoin 
to obtain similar efficacy without significant adverse effects with only once daily usage.   
 
Conclusion:  Minoxidil is safe and efficacious in the treatment of male AGA especially at the 
strength of 5% in either foam or solution preparation for twice daily use.  
 
Key Words:  minoxidil, androgenetic alopecia, men 
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Introduction 
 
 Male androgenetic alopecia (AGA), also known as male pattern hair loss (MPHL), is 
characterized by the miniaturization of the hair follicles in the frontal and parietal scalp.
1 
 It is the 
most common form of alopecia in men with most men developing some degree of recession of 
the hairline during their lifetime, and although prevalence may vary, severe MPHL can be seen 
in around 50% of men beyond age 40.
2,3
  In 2012, there were 704,593 male patients worldwide 
that sought care for MPHL.
4 
 Of these, 458,271 were nonsurgical patients, and 246,321 were 
treated with hair restoration surgery.
4 
 Considering these numbers, physician assistants can 
expect to encounter men with this condition frequently in our practice whether it may be in a 
primary care or a more specialized dermatologic setting.   
 There is no exact number for the total health care cost of treating male AGA, and the cost 
varies significantly depending on the type of treatments.  For example, the median cost of 
minoxidil for one month use varies from $16.04 for Rogaine Mens External 5% foam, to $27.37 
for Rogaine Mens Extra Strength External 5% foam.
 5
  For those opting for hair restoration 
surgery, it can be done via one of two ways: follicular unit transplantation (FUT) or follicular 
unit extraction (FUE).
6 
 The cost for FUT ranges from $3-$9 per graft depending on the location 
of the practice, while FUE can cost anywhere from $6.50-$12 per graft.
6  
 
As for the cause of male AGA, there is not one defining etiology, rather this condition 
develops as a result of various factors with the two most contributory being androgen 
hyperactivity and genetic predisposition to hair loss related sensitivity to androgen actions.
2 
 
Dihydroxytestosterone (DHT) synthesized from testosterone by an enzyme called 5α-reductase is 
thought to be the principal agent responsible for MPHL.
2
  DHT binds more potently to androgen 
receptors than testosterone and is found localized to hair follicles.
2
  Consistent higher levels of 
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5α-reductase as well as DHT are found in men with MPHL versus those without balding scalps.2  
Additionally, some men have genetically more enhanced androgen receptors that are more 
responsive to the actions of DHT, and thus are more likely to develop AGA.
2
  Male AGA often 
presents clinically with consistently identifiable patterns as categorized by the Hamilton-
Norwood classification ranging from type I-VIII based on the severity of hairline recession.
2 
  
 Male AGA is a progressive condition, and there is currently not one treatment that is 
considered to be the gold standard.  Currently, two FDA-approved pharmaceutical options used 
for male AGA are topical minoxidil and oral finasteride.
2
  Finasteride is a 5α-reductase inhibitor 
that works to prevent the conversion of testosterone to DHT, and as DHT is the principal agent 
responsible for MPHL, decreased DHT means a decrease in hair loss.
7 
 Minoxidil, on the other 
hand, has no known mechanism of action like finasteride.  It was first developed to be an oral 
antihypertensive agent, and hypertrichosis was observed as a side effect in some patients, which 
led to its formulation as a topical agent for AGA.
8 
 Minoxidil was observed to enhance the size of 
the hair follicles and stimulate and prolong the anagen (growth) phase of the hair cycle, resulting 
in increased hair count and thicker hair shafts that stay on the scalp for a longer period of time.
2,8  
In addition to pharmaceutical therapy, other treatment methods include low-level laser 
light therapy or hair restoration surgery.
2
  The mechanism of action of laser light therapy is not 
fully understood, and its efficacy is still questionable.
2  
As for hair restoration surgery, it is the 
only permanent but also the most invasive method to treat male AGA.  Besides these treatment 
options, nonmedical therapy is also available in the form of hairpieces.
2 
 
 Minoxidil, when compared to the medical alternatives, is the least invasive form of 
treatment due to its delivery as a topical agent with minimal systemic absorption.
2 
 Nevertheless, 
minoxidil has been suggested to cause tachycardia, hypotension, and even increased incidence of 
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coronary artery disease in a subset of men with AGA due to its origin as an antihypertensive 
agent.
2 
 Furthermore, it comes in different formulations like foam or combined with tretinoin, 
and there has been no systematic review to reexamine its safety and efficacy since 2007 as well 
as to assess the optimal strength and means of delivery.  
Objective 
 
 The objective of this systematic review is to determine whether or not minoxidil is 
efficacious and safe for the treatment of AGA in men, and if so, what is the optimal strength and 
means of delivery.  
Methods 
 
 In selecting the studies for this review, the author applied the following criteria.  The 
articles had to be double-blind, randomized controlled trials that studied men between the ages of 
18 and 49 years with AGA, and all were published in English in peer reviewed journals.  The 
interventions in these studies were various strengths and formulations of minoxidil.  The studies 
compared those in the treatment group receiving minoxidil to those receiving a placebo or a 
different preparation of minoxidil.  The outcomes measured include the efficacy and safety of the 
various minoxidil interventions in treating men with AGA. 
 In searching the articles for this review, key words used included minoxidil, androgenetic 
alopecia, and men. The studies were selected from PubMed for their relevance to the clinical 
question.  Inclusion criteria required that the studies must be randomized controlled trials 
published after 1/1/2007 with patient oriented outcomes such as improvement in hair growth.  
Exclusion criteria included females, patients with other medical problems such as uncontrolled 
hypertension or other scalp conditions, patients that used minoxidil or other hair growth products 
prior to study, patients with untreated cancer, or history of radiation to the scalp or chemotherapy 
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within the previous year, or history of hair transplants or scalp reduction surgery, and patients on 
systemic steroids for more than fourteen days within the last two months.  Statistics reported or 
used included p-values, relative benefit increase (RBI), absolute benefit increase (ABI), numbers 
needed to treat (NNT), relative risk increase (RRI), absolute risk increase (ARI), and numbers 
needed to harm (NNH).  Table 1 displays the demographics and characteristics of each study. 
Table 1-Demographics and characteristics of included studies 
Study Type # Pt Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Olsen
9
 
(2007) 
Double 
blind 
RCT 
352 18-49, 
mean 
39.2 
Hamilton-
Norwood 
patterns IIIv, 
IV, or V male 
pattern hair 
loss who were 
otherwise in 
good health 
(1) known sensitivity to 
minoxidil, (2) use of any 
OTC/Rx medication for 
hair growth within last 6 
months, (3) use of 5 
alpha-reductase 
inhibitors, isotretinoin, 
had radiation to the 
scalp, or chemotherapy 
in the previous year, (4) 
use of botanicals 
/ neutraceuticals for hair 
regrowth within the prior 
3 months, (5) use of 
systemic steroids > 14 
days in the past 2 
months.  
(6) Other exclusions
6
 
37 
5% minoxidil 1g 
BID 
 
Shin
3
 
(2007) 
Double 
blind 
RCT 
31 28-45, 
mean 
39.7 ± 
4.5 
years 
Hamilton-
Norwood 
classification 
type III-V 
other medical problems, 
use of any products or 
drugs affecting hair 
growth for ≥ 6 months 
prior to the study 
2 1. Control group 
application of 5% 
minoxidil 1 mL 
BID 
2. Test group-one 
application of a 
placebo in the 
morning and then 
one application of 
5% minoxidil / 
0.01% tretinoin at 
night 
Tsuboi
1
 
(2009) 
Double 
blind 
RCT 
300 ≥ 20, 
mean 
40.6 ± 
6.65 
years 
Diagnosed 
within the last 
10 years with 
AGA as 
classified by 
Ogata 
None was mentioned in 
study. 
15 Group 1-
application of 5% 
minoxidil 1 mL 
BID 
Group 2-
application of 1% 
minoxidil 1 mL 
BID 
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Outcomes Measured 
 
Outcomes measured for efficacy included mean change from baseline in hair count, 
subject assessment, and expert assessment.  In the Olsen study, mean change from baseline in 
hair count was determined via target area hair count (TAHC) at baseline and at conclusion.  
Subject assessments and expert assessments were recorded on separate 7-point scales with 
slightly different wordings on each scale as appropriate to each audience.  Similarly in the Shin 
study, efficacy was assessed via macrophotographic image at baseline and at conclusion looking 
at total hair count, non-vellus hair count, anagen hair ratio, linear hair growth rate, and mean hair 
diameter.  Efficacy was also measured by patient assessment of improvement and satisfaction 
based on a 10-point scale as well as by expert GPR recorded as one of five gradings.  The Tsuboi 
study also examined efficacy via hair counting at baseline and at conclusion of non-vellus, 
vellus, terminal, and non-terminal hair as well as assessments of hair growth by subjects and 
experts using the same 5-point scale. 
To assess safety, the studies used subject report of symptoms of scalp irritation (burning, 
itching, stinging) and investigator examination of signs of scalp irritation (dryness/scaling, 
folliculitis, erythema).  Any finding either mild or moderate reported by subjects or seen by 
investigators were recorded as having scalp irritation.  Safety was also measured via change in 
vital signs and/or abnormal laboratory values to account for systemic effects.   
Results 
 
 In order to review the studies the 16
th
 week was chosen as the point of comparison for the 
Olsen and Tsuboi studies while the closest measured time period of the 18
th
 week was chosen for 
the Shin study.  Additionally, worst-case analyses were done for all studies to ensure the most 
accurate review.  According to Table 2, the mean change from baseline for change in hair 
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count/cm
2
 shows 20.9 for 5% minoxidil foam BID versus 4.7 for placebo, 22.3 for 5% minoxidil 
solution BID versus 17.2 for 1% minoxidil solution BID, and 17.3 for 5% minoxidil/0.1% 
tretinoin once a day versus 12.9 for 5% minoxidil solution BID.  The Olsen study reported 
significance with p-value < 0.0001 for the 5% minoxidil versus placebo, and the Tsuboi study 
reported that the difference between the 5% and 1% groups was significant based on two-sided 
CI of 1.3-8.8 and a significant p-value of 0.009.
1,9 
  
Table 2-Efficacy based on change in hair count 
Study Comparison Mean change from baseline  
(hair count/cm
2
) 
P-value 
Olsen
9
 (2007) 5% minoxidil foam BID 20.9 
<0.0001 
Placebo 4.7 
Tsuboi
1
 (2009) 5% minoxidil solution BID 22.3 
0.009 
1% minoxidil solution BID 17.2 
Shin
3
 (2007) Placebo AM, 5% minoxidil 
solution / 0.01% tretinoin PM 
17.3 
NS 
5% minoxidil solution BID 12.9 
 
In terms of subject assessment and expert assessment of hair growth, results were 
converted into dichotomous data for both Olsen and Tsuboi studies.  Based on the subject 
assessment, the Olsen study reported 70.6% of the minoxidil patients with improved hair growth 
as compared to 48.3% of patients on placebo, yielding a significant p-value <0.0001 (Table 3).  
The corresponding NNT was 5, meaning that for every five patients treated with 5% minoxidil 
foam BID, one will see slight improvement or better in hair growth as compared to placebo 
(Table 3).  For those with moderate improvement or better in hair growth, the numbers are 48% 
for 5% minoxidil versus 21.5% for placebo, giving a NNT of 4 (Table 3). The Tsuboi study 
reported 67% of minoxidil patients on 5% solution saw improvement versus 62% of patients on 
1% solution, yielding a non-significant p-value of 0.330 with a NNT of 19 (Table 3).  Limited to 
those with moderate improvement or better, the numbers become 24% versus 16%, resulting in a 
non-significant p-value of 0.087 with a NNT of 13 (Table 3). 
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Table 3-Efficacy based on subject and expert assessment 
 Study Comparison Improvement 
from baseline   
RBI ABI NNT P-value 
S
u
b
je
ct
 A
ss
es
sm
en
t 
o
f 
H
ai
r 
G
ro
w
th
 
Olsen
9
 (slight or better) 5% minoxidil foam BID 70.6% 
46% 22% 5 <0.0001 
Placebo 48.3% 
Olsen
9
 (moderate or 
better) 
5% minoxidil foam BID 48% 
122% 26% 4 N/A 
Placebo 21.5% 
Tsuboi
1
 (slight or 
better) 
5% minoxidil solution BID 67% 
9% 5% 19 0.33 
1% minoxidil solution BID 62% 
Tsuboi
1
 (moderate or 
better) 
5% minoxidil solution BID 24% 
51% 8% 13 0.087 
1% minoxidil solution BID 16% 
Shin
3
 Placebo AM, 5% minoxidil 
solution / 0.01% tretinoin PM 
4.2 
N/A NS 
5% minoxidil solution BID 3.8 
E
x
p
er
t 
A
ss
es
sm
en
t 
o
f 
H
ai
r 
G
ro
w
th
 
Olsen
9
 (slight or better) 5% minoxidil foam BID 38.3% 
94% 19% 6 <0.0001 
Placebo 19.8% 
Olsen
9
 (moderate or 
better) 
5% minoxidil foam BID 8% 
1238% 7% 14 N/A 
Placebo 1% 
Tsuboi
1
 (slight or 
better) 
5% minoxidil solution BID 81% 
5% 4% 27 0.435 
1% minoxidil solution BID 77% 
Tsuboi
1
 (moderate or 
better) 
5% minoxidil solution BID 31% 
80% 14% 8 0.007 
1% minoxidil solution BID 17% 
Shin
3
 Placebo AM, 5% minoxidil 
solution / 0.01% tretinoin PM 
1.6 
N/A NS 
5% minoxidil solution BID 1.8 
 
As for the expert assessment, the Olsen study showed 38.3% of patients on minoxidil 
seeing an improvement in hair growth as compared to 19.8% of those on placebo, yielding a 
significant p-value <0.0001 with a corresponding NNT of 6 (Table 3).  For the moderate 
improvement, the numbers are 8% versus 1% with a resulting NNT of 14 (Table 3).  In the 
Tsuboi study, no significance was found when assessing slight or better improvement in hair 
growth, however the results measuring moderate improvement of hair growth show 31% for the 
5% group and 17% for the 1% group, yielding a significant p-value of 0.007 with a 
corresponding NNT of 8 (Table 3).  In the Shin study, the mean changes from baseline of 3.8 for 
5% minoxidil BID and 4.2 for the combined product based on subject assessment and 1.8 and 1.6 
respectively for expert assessment show no significant difference (Table 3).  
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 For measuring safety, the results were converted into dichotomous data with the 
exception of the Tsuboi study, which did not report any symptoms of scalp irritations, and the 
Shin study, which did not report any data to account for systemic effects.   In the Olsen study, 
one can see that 6% of patients using 5% minoxidil foam BID experienced at least one of the 
symptoms of scalp irritation versus 2% of those on placebo (Table 4).  The corresponding NNH 
was 31, meaning that for every 31 patients using 5% minoxidil foam BID, one will experience at 
least one of the symptoms of scalp irritation as compared to placebo (Table 4).  As for the Shin 
study, this indicated that 31% of patients on the combined product experienced symptoms of 
scalp irritation versus 27% of those using 5% solution BID alone with a NNH of 22 (Table 4).   
Table 4-Safety based on subject report, investigator assessment, and systemic effects  
 Study Comparison Percentage of 
Patients with   
RRI ARI NNH P-value 
S
u
b
je
ct
 R
ep
o
rt
 
O
f 
S
ca
lp
 I
rr
it
at
io
n
 Olsen
9
 
(2007) 
5% minoxidil foam BID 6% 
139% 3% 31 N/A 
Placebo 2% 
Tsuboi
1
 
(2009) 
5% minoxidil solution BID 
N/A 
1% minoxidil solution BID 
Shin
3 
(2007) 
Placebo AM, 5% minoxidil 
solution / 0.01% tretinoin PM 
31% 
17% 4.6% 22 N/A 
5% minoxidil solution BID 27% 
In
v
es
ti
g
at
o
r 
A
ss
es
sm
en
t 
O
f 
S
ca
lp
 I
rr
it
at
io
n
 
Olsen
9
 
(2007) 
5% minoxidil foam BID 7% 
-11% -1% -109 N/A 
Placebo 8% 
Tsuboi
1
 
(2009) 
5% minoxidil solution BID 8% 
200% 5% 19 0.040 
1% minoxidil solution BID 3% 
Shin
3 
(2007) 
Placebo AM, 5% minoxidil 
solution / 0.01% tretinoin PM 
0% 
-100% -13% -8 N/A 5% minoxidil solution BID 13% 
C
h
an
g
e 
in
 v
it
al
 
si
g
n
s 
 a
n
d
/o
r 
ab
n
o
rm
al
 l
ab
s 
Olsen
9
 
(2007) 
5% minoxidil foam BID 1% 
-52% -1% -165 N/A 
Placebo 1% 
Tsuboi
1
 
(2009) 
5% minoxidil solution BID 1% 
-33% -1% -150 N/A 
1% minoxidil solution BID 2% 
Shin
3 
(2007) 
Placebo AM, 5% minoxidil 
solution / 0.01% tretinoin PM N/A 
5% minoxidil solution BID 
 
Based on investigator assessment, the Olsen study reported 7% of patients on 5% 
minoxidil foam BID to show at least a sign of scalp irritation versus 8% of patients on placebo 
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(Table 4).  The corresponding NNH was calculated to be negative, with a value of -109, 
indicating that for every 109 patients treated with 5% minoxidil foam BID, one fewer patient 
would show signs of scalp irritations when compared to placebo (Table 4).  The Tsuboi study 
reported 8% of patients on 5% minoxidil solution with at least one sign of scalp irritation versus 
3% of those using 1% with NNH of 19 (Table 4). This was a significant finding considering the 
p-value of 0.040 (Table 4).  The Shin study showed no patients having signs of scalp irritation on 
the combined product whereas 13% of patients on 5% minoxidil solution BID had signs of scalp 
irritation as examined by the investigators (Table 4).  The corresponding NNH was -8 (Table 4). 
 As for systemic adverse effects, the Olsen study reported 1% (1/180) of patients on 5% 
minoxidil foam BID as well as 1% (2/172) of patients on placebo to have increased blood 
pressure and/or body weight (Table 4).
9 
 When these subjects had blood drawn for further 
investigations, serum minoxidil levels were within normal limits and well below the threshold 
for cardiac-related events.
9 
 Once the NNH was calculated, it was -165 (Table 4).  The Tsuboi 
study reported 1% (2/150) of patients on 5% minoxidil solution and 2% (3/150) of patients on 
1% minoxidil with abnormal lab values that included increased eosinophil count and increased 
total bilirubin (Table 4).
1 
 However, the study stated that the changes were mild with all subjects 
recovering without treatment, and specifically emphasized that there were no cardiac-related 
adverse events in either group.
1 
 The corresponding NNH was -150 (Table 4). 
Discussion 
In terms of efficacy, Table 2 shows the mean changes from baseline for all formulations 
of minoxidil exceeding the 4.7 for placebo. Table 2 data further suggests 5% minoxidil solution 
BID to be most efficacious based on having the highest change in hair count from baseline of 
22.3.  However, this number is not substantially different from the 20.9 for 5% minoxidil foam 
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BID, so the efficacy of 5% solution as compared to 5% foam is very comparable.  Indeed an 
absolute conclusion cannot be made that solution is a better means of delivery given the disparity 
between the data for 5% minoxidil solution BID reported by the Shin study with a mean change 
in hair count of only 12.9 as opposed to 22.3 reported by the Tsuboi study.  This discrepancy 
could be due to differences in study design.  In the Tsuboi study, hair counting was recorded as 
the median count done blind on the monitor by five well-trained individuals.
1 
 In contrast, the 
Shin study used computer image analysis software to count the hair.
3
   
Analysis of subject and expert assessment continues to support the efficacy of minoxidil 
in that there is a significant difference seen in improvement of hair growth going from placebo to 
5% minoxidil foam BID given p-values <0.0001 with a NNT of five patients.  Interestingly, 
looking at those with moderate improvement or better in hair growth, the NNT improved further 
to four based on subject assessment.  The Tsuboi study also reported their results with the same 
granularity, with the expert assessment of moderate improvement in hair growth showing a 
significant p-value of 0.007 and corresponding NNT of eight, demonstrating that 5% minoxidil 
solution is more efficacious than the 1% minoxidil solution for patients seeking moderate 
improvement or better in hair growth, which one can assume most patients with AGA want. 
Assessing the efficacy of foam versus solution delivery the subject and expert 
assessments cannot be used objectively to compare treatments across studies as presumably each 
study might have had different criteria for what a “slight” or “moderate” improvement was.  
Therefore, in light of the inconclusive results when comparing change in hair count numbers, it 
is not possible to determine whether foam or solution is a more efficacious means of delivery.  
 In terms of safety, subject report of symptoms of scalp irritation such as itching, burning, 
or stinging showed 6% (10/180) of patients in the 5% minoxidil foam BID versus 2% (4/172) in 
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the placebo group, yielding a NNH of 31 (Table 4).  However, when expert assessment is also 
taken into consideration, one can see that there were more patients (8%) in the placebo group 
that reported symptoms versus 7% of patients in the 5% minoxidil foam BID, yielding a NNH of 
-109.  This combined with the lack of systemic adverse effect establishes 5% minoxidil as safe.   
As for determining the safer means of minoxidil delivery via foam or solution, the 
numbers for systemic adverse effects are inconclusive, showing equal percentages of patients in 
both groups (1%) experiencing some kind of change in vital signs and/or abnormal lab values 
(Table 4).  In terms of minor side effects, such as scalp irritation, the numbers are fairly close 
under investigator assessment, but under subject report only 6% of patients for foam reported 
scalp irritation versus 27% of patients for solution (Table 4).  Due to the subjective nature of the 
subject assessments, such data cannot be used conclusively to compare treatments across studies.   
Conclusion 
Based on this systematic review and the chosen studies, minoxidil is safe and efficacious 
in the treatment of male AGA especially at the optimal strength of 5% in either foam or solution 
preparation for twice daily use.  The data within these three studies are consistent with the 
beneficial effects of minoxidil as well as its overall safety with no systemic adverse effects.  
Future studies should expand on the Shin study with a larger sample size to investigate the 
possibility of the combined product of 5% minoxidil/0.01% tretinoin.  Since there is usually an 
inverse relationship between administration frequency and compliance with medication, this 
combined product would provide a good alternative in terms of increasing compliance as it only 
requires once daily application versus the twice daily minoxidil only treatments.
3 
 Another area 
that future studies can look into is a comparative assessment of minoxidil to finasteride as well as 
an investigation of possible synergistic benefits if combined in the treatment of male AGA. 
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